Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

DNA Ginkgo Bioworks Holdings, Inc.

This repo contains Python code to generate the global dataset of factor returns, stock returns, and firm characteristics from “Is there a Replication Crisis in Finance?” by Jensen, Kelly, and Pedersen ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, ...

Factor has launched the new One aero race bike, claimed to be the “fastest UCI-legal road bike in the world”. Formerly known as the ‘Prototype’, which made its racing debut under select Israel–Premier ...

Factor meals provides fully prepared meals designed by registered dietitians. Meal delivery is a convenient meal solution for busy individuals looking to maintain a balanced diet. Our testers tried ...

Abstract: To address the issues of significant cumulative errors and the inability to track in real time in traditional state of charge (SOC) estimation methods for energy storage batteries, this ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Eric's career includes extensive work ...